View Filing Data

Cover Page - USD ($)	11 Months Ended
Cover Page - USD ($)	Dec. 31, 2019	May 06, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Period End Date	Dec. 31, 2019
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Document Annual Report	true
Document Transition Report	false
Entity Registrant Name	Upjohn Inc
Entity Central Index Key	0001792044
Entity File Number	000-56114
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-4364296
Entity Address, Address Line One	235 East 42nd Street
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	733-2323
No Trading Symbol Flag	true
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	true
Entity Public Float	$ 0
Entity Common Stock, Shares Outstanding		100

Consolidated Statement of Income	11 Months Ended
Consolidated Statement of Income	Dec. 31, 2019 USD ($) $ / shares shares
Income Statement [Abstract]
Revenues	$ 0
Operating expenses	0
Other (income)/deductions—net	0
Income before provision/(benefit) for taxes on income	0
Provision/(benefit) for taxes on income	0
Net income	$ 0
Earnings per common share—basic \| $ / shares	$ 0
Weighted-average common shares—basic \| shares	100

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statement of Comprehensive Income	11 Months Ended
Consolidated Statement of Comprehensive Income	Dec. 31, 2019 USD ($)
Net income	$ 0
Other comprehensive income/(loss) before tax	0
Tax provision/(benefit) on other comprehensive income/(loss)	0
Other comprehensive income/(loss)	0
Comprehensive income attributable to Upjohn Inc.	$ 0

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Balance Sheet	Dec. 31, 2019 USD ($)
Assets
Total current assets	$ 0
Total assets	0
Liabilities and Equity
Total current liabilities	0
Total liabilities	0
Commitments and Contingencies
Common stock, $0.01 par value; 1,000 shares authorized; issued: 2019—100 shares	1
Additional paid-in capital	0
Due from shareholder	(1)
Retained earnings	0
Accumulated other comprehensive income/(loss)	0
Total Upjohn Inc. shareholder's equity	0
Total liabilities and equity	$ 0

Consolidated Statement of Equity - 11 months ended Dec. 31, 2019 - USD ($)	Total	Common Stock [Member]	Add'l Paid-In Capital [Member]	Due From Share Holder [Member]	Retained Earnings [Member]	Accum. Other Comp. Income/ (Loss) [Member]
Initial capitalization, February 14, 2019 (date of incorporation), Shares at Feb. 13, 2019		100
Initial capitalization, February 14, 2019 (date of incorporation) at Feb. 13, 2019	$ 0	$ 1	$ 0	$ (1)	$ 0	$ 0
Net income	0
Other comprehensive income/(loss), net of tax	0
Balance (Shares) at Dec. 31, 2019		100
Balance at Dec. 31, 2019	$ 0	$ 1	$ 0	$ (1)	$ 0	$ 0

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statement of Cash Flows	11 Months Ended
Consolidated Statement of Cash Flows	Dec. 31, 2019 USD ($)
Operating Activities
Net income	$ 0
Adjustments to reconcile net income to net cash provided by operating activities:
Other changes in assets and liabilities:	0
Net cash provided by operating activities	0
Investing Activities
Net cash provided by investing activities	0
Financing Activities
Net cash provided by financing activities	0
Effect of exchange-rate changes on cash and cash equivalents	0
Net increase/(decrease) in cash and cash equivalents	0
Cash and cash equivalents, beginning	0
Cash and cash equivalents, end	0
Supplemental Cash Flow Information
Income taxes	0
Interest	$ 0

Organization and Basis of Presentation	11 Months Ended
Organization and Basis of Presentation	Dec. 31, 2019
Accounting Policies [Abstract]
Organization and Basis of Presentation	Note 1. Organization and Basis of Presentation A. Organization Upjohn Inc. (the “Company” or “Upjohn”), a Delaware corporation, was formed on February 14, 2019, and is currently a wholly-owned subsidiary of Pfizer Inc. (“Pfizer”). The Company has two wholly-owned subsidiaries, Utah Acquisition Holdco Inc. and Utah Acquisition Sub Inc., both of which are Delaware corporations formed on July 25, 2019. The Company and its subsidiaries have not commenced operations, have no significant assets or liabilities and have not conducted any material activities other than those incidental to its formation from February 14, 2019, its date of incorporation, through December 31, 2019. On February 13, 2020, the United States Securities and Exchange Commission (the “SEC”) declared effective the Registration Statement on Form S-4, as amended (the “Registration Statement”), of the Company to register shares of its common stock, par value $0.01 per share, that will be issued and distributed in connection with a series of agreements entered into by Pfizer, the Company, Mylan N.V. (“Mylan”) and certain of their affiliates to combine Pfizer’s global, primarily off-patent branded and generic established medicines business (the “Upjohn Business”) with Mylan in an all-stock Reverse Morris Trust transaction (the “Transaction”), creating a new global pharmaceutical company. On July 29, 2019, Pfizer announced it had entered into a definitive agreement to combine the Company with Mylan. Under the terms of the Transaction, Pfizer will contribute the Upjohn Business, a business unit of Pfizer, to the Company. The Company will be spun-off or split-off to Pfizer’s stockholders and, immediately thereafter, combined with Mylan. The name of the new company to be formed by the planned combination of the Upjohn Business and Mylan will be “Viatris.” The voting common stock of the Company is expected to be listed for trading on the NASDAQ. Pfizer stockholders would own 57% of the combined new company, and former Mylan shareholders would own 43%. The Company will issue $12 billion of debt in connection with its separation from Pfizer and will make a cash payment to Pfizer equal to $12 billion as partial consideration for the contribution of the Upjohn Business from Pfizer to the Company. The Transaction is generally expected to be tax free to Pfizer and Pfizer stockholders and is expected to close in the second half of 2020, subject to Mylan shareholder approval and satisfaction of other customary closing conditions, including receipt of regulatory approvals. B. Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and present the consolidated balance sheet of the Company as of December 31, 2019 and the related consolidated statements of income, comprehensive income, equity and cash flows of the Company for the period from February 14, 2019 (date of incorporation) to December 31, 2019. Preparing financial statements requires management to make estimates and assumptions that affect the amounts that are reported in the financial statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from these estimates. At December 31, 2019, Due from shareholder represents a receivable from Pfizer of $ 1 in connection with the issuance of the Company’s common stock (see Note 2).

Organization and Basis of Presentation - Additional Information (Detail) - USD ($)	6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Jul. 29, 2019
Common stock, par value		$ 0.01
Due from shareholder		$ 1
Pfizer Stockholders [Member]
Ownership percent			57.00%
Pfizer Stockholders [Member] \| Scenario Forecast [Member]
Debt in connection with its separation from parent company	$ 12,000,000,000
Business combination, consideration transferred	$ 12,000,000,000
Mylan Shareholders [Member]
Ownership percent			43.00%

Equity - Additional Information (Detail)	Dec. 31, 2019 $ / shares shares
Stockholders' Equity Note [Abstract]
Common stock, shares authorized	1,000
Common stock, par value \| $ / shares	$ 0.01
Common stock, shares issued	100
Common stock, shares outstanding	100

Consolidated Balance Sheet (Parenthetical)	Dec. 31, 2019 $ / shares shares
Statement of Financial Position [Abstract]
Common stock, par value \| $ / shares	$ 0.01
Common stock, shares authorized	1,000
Common stock, shares issued	100

Equity	11 Months Ended
Equity	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Equity	Note 2. Equity As of December 31, 2019, the Company is authorized to issue 1,000 shares of common stock, par value $0.01 per share. As of December 31, 2019, there were 100 shares of common stock, par value of $0.01 per share, of the Company issued and outstanding. All such issued and outstanding shares of common stock were held by Pfizer.